

Aubagne, France | April 9, 2025

## Sartorius Stedim Biotech and Tulip Partner to Drive End-to-End Biomanufacturing Visibility and Optimization

- The partnership will tackle key challenges in single-use bioprocessing
- Enabling customers to scale digital capabilities while reducing process variability and ensuring regulatory compliance

Sartorius Stedim Biotech is entering a strategic partnership with Tulip Interfaces, a leader in frontline operations technology, to accelerate digital transformation in biopharmaceutical manufacturing. The partnership enables Sartorius Stedim Biotech to deliver robust digital solutions powered by Tulip to overcome critical challenges in single-use bioprocessing.

The companies are combining capabilities to develop Biobrain® Operate powered by Tulip, a cutting-edge suite of digital manufacturing applications designed to integrate seamlessly with Sartorius Stedim Biotech process equipment. Biobrain® Operate powered by Tulip is the latest addition to the Sartorius Stedim Biotech's portfolio of Biobrain® technologies, and leverages a no-code, frontline operations platform developed by Tulip.

The solution overcomes key challenges in single-use bioprocessing, like inconsistencies and errors in manual operations, paper-based record-keeping, lengthy process review times, and supply chain traceability, enabling customers to scale their digital manufacturing capabilities while reducing process variability and ensuring regulatory compliance.

Roey Mechrez, Head of Ecosystem, GM EMEA at Tulip, said, "This partnership with Sartorius Stedim Biotech is a major milestone in our mission to bring no-code, connected frontline operations to the biopharma industry. By combining Sartorius Stedim Biotech's deep expertise in biopharmaceutical production with Tulip's intuitive, composable platform, we are enabling customers to digitize their operations with unprecedented speed and flexibility. Together, we are driving innovation in the field of human-machine interface (HMI), offering a composable HMI that seamlessly integrates machine data with execution and production data to create more intelligent and responsive manufacturing environments."

Michaela Pischke, Head of Separations Technologies at Sartorius Stedim Biotech, said, "Digitalization is a key driver of efficiency in biopharmaceutical manufacturing, and our partnership with Tulip will allow us to provide customers with advanced digital solutions tailored to their specific needs. Tulip's no-code technology aligns perfectly with our vision of enabling seamless, data-driven decision-making across the production floor."

The partnership addresses the biopharmaceutical industry's growing demand for flexible, user-friendly digital solutions. By combining cutting-edge technology from Tulip with industry expertise from Sartorius, the collaboration will help manufacturers streamline operations, ensure quality, and accelerate time to market.

In this collaboration, Sartorius Stedim Biotech continues its commitment to sustainability by advancing paperless manufacturing, optimizing resource efficiency, and reducing waste in bioprocessing. By developing smarter, more digitalized solutions for customers, Sartorius and Tulip are enabling more efficient, biopharmaceutical production and promoting thoughtful resource use in biomanufacturing.

### **A profile of Tulip Interfaces:**

Tulip, the leader in frontline operations, is helping companies around the world equip their workforce with AI-enabled, connected apps—leading to higher quality work, improved efficiency, and end-to-end traceability across operations. With Tulip's cloud-based platform, those closest to operations can take advantage of composability and edge connectivity to digitally transform processes, guide operators, track production, and gain a real-time, holistic view of operations. A spinoff out of MIT, the company is headquartered in Boston, MA, with offices in Germany, Singapore, and Hungary.

Visit Tulip Interfaces [www.tulip.co](http://www.tulip.co)

### **A profile of Sartorius Stedim Biotech:**

Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a provider of innovative solutions, the company based in Aubagne, France, helps its customers to manufacture biotech medications, such as cell and gene therapies, safely, rapidly, and sustainably. The shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris. The company has a strong global reach with manufacturing and R&D sites as well as sales entities in Europe, North America, and Asia. Sartorius Stedim Biotech regularly expands its portfolio through acquisitions of complementary technologies. In 2024, the company generated sales revenue of around 2.8 billion euros. Currently, more than 9,900 employees are working for customers around the globe.

Visit our [Newsroom](#) or follow us on [LinkedIn](#).

### **Contact**

Michaela Pischke  
Head of Business Area Separation Technologies  
Bioprocess Solutions Division  
+495513083179  
[Michaela.Pischke@sartorius.com](mailto:Michaela.Pischke@sartorius.com)

Lars Hanf  
Head of Marketing  
Bioprocess Solutions Division  
+495513084492  
[Lars.Hanf@sartorius.com](mailto:Lars.Hanf@sartorius.com)